Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Pharmacotherapies for obesity: past, current, and future therapies.

Ioannides-Demos LL, Piccenna L, McNeil JJ.

J Obes. 2011;2011:179674. doi: 10.1155/2011/179674.

2.

Pharmacotherapy for obesity.

Ioannides-Demos LL, Proietto J, McNeil JJ.

Drugs. 2005;65(10):1391-418. Review.

PMID:
15977970
3.

Meta-analysis: pharmacologic treatment of obesity.

Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC.

Ann Intern Med. 2005 Apr 5;142(7):532-46.

PMID:
15809465
4.

Anti-obesity drugs: a review about their effects and their safety.

Derosa G, Maffioli P.

Expert Opin Drug Saf. 2012 May;11(3):459-71. doi: 10.1517/14740338.2012.675326. Review.

PMID:
22439841
5.

Safety of antiobesity drugs.

Cheung BM, Cheung TT, Samaranayake NR.

Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi: 10.1177/2042098613489721.

6.

[Recent progress and novel perspectives on obesity pharmacotherapy].

Faria AM, Mancini MC, Melo ME, Cercato C, Halpern A.

Arq Bras Endocrinol Metabol. 2010 Aug;54(6):516-29. Review. Portuguese.

7.

New and emerging drug molecules against obesity.

George M, Rajaram M, Shanmugam E.

J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76. doi: 10.1177/1074248413501017. Review.

PMID:
24064009
8.

Drug treatment of obesity: current status and future prospects.

Kakkar AK, Dahiya N.

Eur J Intern Med. 2015 Mar;26(2):89-94. doi: 10.1016/j.ejim.2015.01.005. Review.

PMID:
25634851
9.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

10.

Pharmacotherapy for obesity.

Joo JK, Lee KS.

J Menopausal Med. 2014 Dec;20(3):90-6. doi: 10.6118/jmm.2014.20.3.90. Review.

11.

Pharmacological intervention: the antiobesity approach.

Rissanen A.

Eur J Clin Invest. 1998 Sep;28 Suppl 2:27-30. Review.

PMID:
9777325
12.

New obesity agents: lorcaserin and phentermine/topiramate.

Fleming JW, McClendon KS, Riche DM.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):1007-16. doi: 10.1345/aph.1R779. Review.

PMID:
23800750
13.

Pharmacologic options for the treatment of obesity.

Campbell ML, Mathys ML.

Am J Health Syst Pharm. 2001 Jul 15;58(14):1301-8. Review.

PMID:
11471477
14.

Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis.

Neovius M, Johansson K, Rössner S.

Obes Rev. 2008 Sep;9(5):420-7. doi: 10.1111/j.1467-789X.2008.00463.x. Review.

PMID:
18208467
15.

Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.

Nigro SC, Luon D, Baker WL.

Curr Med Res Opin. 2013 Jul;29(7):839-48. doi: 10.1185/03007995.2013.794776. Review.

PMID:
23574263
16.

Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.

Sweeting AN, Tabet E, Caterson ID, Markovic TP.

Diabetes Metab Syndr Obes. 2014 Feb 12;7:35-44. doi: 10.2147/DMSO.S38979. Review.

17.

Current concepts in the pharmacological management of obesity.

Carek PJ, Dickerson LM.

Drugs. 1999 Jun;57(6):883-904. Review.

PMID:
10400403
18.

Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.

Verpeut JL, Bello NT.

Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Review.

PMID:
24766397
19.

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.

Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J.

Arch Intern Med. 2004 Jul 12;164(13):1395-404. Review.

PMID:
15249348
20.
Items per page

Supplemental Content

Support Center